Risk-Benefit of IBD Drugs: A Physicians and Patients Survey.
Fiche publication
Date publication
avril 2023
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Vieujean S, Caron B, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Treatment choices for patients with inflammatory bowel disease (IBD) are based on the balance between risks and benefits. Our AI was to compare the perspectives of patients and physicians in evaluating the risks and benefits before initiating therapy for IBD.
Mots clés
benefit-risk, inflammatory bowel disease, patients, physicians
Référence
J Clin Med. 2023 04 24;12(9):